Plasminogen Activator Inhibitor-1; Mutant; Human; Recombinant

Biochem/physiol Actions

Cell permeable: no

Reversible: no

Primary TargetPlasminogen Activator

Product does not compete with ATP.

≥90% by uPA assay.

Target K_i: 5.1 x 106 M-1 sec-1, 7.9 x 105 M-1 sec-1 against uPA and tPA, respectively

General description

Highly purified preparation of an altered form of human PAI-1 containing four mutated amino acids. Mutant PAI-1 is virtually unable to go latent and is stable at elevated temperature and pH for extended periods of time (t_½ = 145 h at 37°C, pH 7.4). Inhibits uPA (K_i = 5.1 x 10⁶ M^-1sec^-1) and tPA (K_i = 7.9 x 10⁵ M^-1sec^-1).

Highly purified preparation of an altered form of human PAI-1 containing four mutated amino acids. Mutant PAI-1 is virtually unable to go latent and is stable at elevated temperature and pH for extended periods of time (t_½ = 145 hours at 37°C, pH 7.4). Inhibits uPA (K_i = 5.1 x 10⁶ M^-1 sec^-1) and tPA (K_i = 7.9 x 10⁵ M^-1 sec^-1).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Berkenpas, M.B., et al. 1995. EMBO J. 14, 2969.

Packaging

50 µg in Plastic ampoule

Please refer to vial label for lot-specific concentration.

Physical form

In 100 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C).

Warning

Toxicity: Standard Handling (A)